Company profile: Alltrna
1.1 - Company Overview
Company description
- Provider of a tRNA therapeutics platform that uses machine learning and high-throughput proprietary in vitro assays to design and optimize therapeutic tRNA molecules for diseases with genetic mutations. Solutions include tRNA medicines that read stop codons to restore full-length protein production, with data-integrated workflows to refine predictive design.
Products and services
- TRNA Medicine for Stop Codon Diseases: Alltrna produces therapeutic-grade tRNA medicines that read stop codons to restore full-length protein production, aiming to treat thousands of diseases
- TRNA Therapeutics Platform: Alltrna architects an AI-driven tRNA therapeutics platform that uses machine learning to design optimized tRNA molecules specifically targeting diseases with genetic mutations for potential therapeutic application
- Machine Learning Integration: Alltrna supplies data-driven machine learning integration that ingests results from tRNA molecule testing to refine predictive models for designing therapeutic tRNAs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Alltrna
The Medicines Company
HQ: United States
Website
- Description: Provider of innovative, cost-effective medicines to the worldwide hospital marketplace, focused on advancing treatment of critical care patients. Markets Angiomax(R) (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex(R).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full The Medicines Company company profile →
Reata Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for cancer, inflammation, neurodegenerative, renal, cardiovascular, and autoimmune diseases, including antioxidant and inflammation-modulating drugs and agents that correct protein misfolding. Offers Skyclarys (omaveloxolone), an FDA-approved treatment for Friedreich's Ataxia in patients 16+.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reata Pharmaceuticals company profile →
Manhattan Pharma
HQ: United States
Website
- Description: Provider of specialty healthcare product development and commercialization focused on innovative treatments for underserved patient populations, advancing a portfolio of product candidates.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Manhattan Pharma company profile →
Eurand
HQ: The Netherlands
Website
- Description: Provider of specialty pharmaceutical and biopharmaceutical products, developing, manufacturing and commercializing a portfolio for cystic fibrosis and gastrointestinal patients in the United States.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eurand company profile →
Novo Nordisk
HQ: Denmark
Website
- Description: Provider of insulin and other diabetes drugs for chronic diseases, GLP-1 treatments for type 2 diabetes, obesity care pharmaceuticals, Mim8 for haemophilia A (weekly or monthly dosing), and ReMed, a recycling program for used injection pens, with a focus on pioneering scientific breakthroughs and expanding access to medicines to prevent and cure disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novo Nordisk company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Alltrna
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Alltrna
2.2 - Growth funds investing in similar companies to Alltrna
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Alltrna
4.2 - Public trading comparable groups for Alltrna
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →